SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs stronger-than-expected quarterly results, first reported public-company profit and rapid growth in AI-compute revenue are driving attention, with traders debating whether the AI business justifies the companys heavy spending. Bulls point to the growth and outlook, while skeptics question cash burn, valuation and upcoming share unlocks; Tesla-merger speculation is an additional topic.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly outlook substantially exceeded expectations, with stronger AI-server demand and improved gross margins driving the rally. Traders largely welcomed the update and speculated about a rerating or short covering, while others questioned whether the unaudited figures and margin gains will hold and flagged execution and cash-flow risks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

SpaceXs results and comments about strong compute demand and scarce capacity have lifted sentiment toward Nebius and other AI cloud providers, challenging oversupply concerns. Bulls see support for the AI infrastructure demand thesis, while bears remain focused on financing risks and the sectors sharp selloff.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results beat earnings expectations, but softer forward guidance and a lower advertising outlook drove a sharp post-earnings selloff. Traders are split between buying the dip as an overreaction and expecting further weakness amid slowing growth, ad-execution concerns, and streaming competition.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias upcoming Q3 report is the main focus, with traders debating whether AI and cloud networking demand and recent AI-RAN partnerships will translate into stronger results. Some expect a positive surprise and a rerating, while others point to the stocks recent weakness and doubt that upbeat AI news will overcome pressure from its legacy telecom business.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets weak, range-bound trading and its scheduled Oct. 28 earnings dominate discussion, with traders focused on whether cloud and AI growth can offset heavy investment spending and cash-flow concerns. Sentiment is split between dip-buyers and bearish traders pointing to persistent underperformance, technical risks, and broader pressure on tech stocks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

SpaceXs strong AI-related results and data-center spending plans, alongside Super Micros sharply higher preliminary sales outlook, fueled discussion of renewed demand for Nvidia hardware and an after-hours rebound; traders also focused on Jensen Huangs GTC Berlin keynote. The reaction is divided, with bullish traders viewing the news as evidence that AI infrastructure spending remains strong while skeptics question its returns and Nvidias ability to sustain momentum.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on the expected completion of Compass Pathways rolling NDA submission for COMP360, its investigational psilocybin therapy for treatment-resistant depression, and the prospect of an accelerated FDA review. Traders are bullish on the approaching regulatory milestone and potential launch, while others are frustrated by the wait and point to volatile price action, broader biotech weakness, and uncertainty around timing and approval.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares are drawing attention after a sharp, high-volume rebound as traders position around the Phase 3 REGAL trials anticipated 80th survival event and final analysis of GPS in AML. Some speculate about a buyout or imminent data, but those claims are unconfirmed; others caution that the trial outcome remains uncertain and the move has occurred without a confirmed catalyst.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals quarterly results beat expectations, but shares sold off as investors focused on a narrower procedure-growth outlook, planned pricing cuts, and a litigation-settlement charge. Traders are split between viewing the decline as an overreaction to solid business growth and seeing the guidance and pricing pressures as reasons for a more cautious outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The CHMP upheld its negative opinion on Omeros European marketing application for YARTEMLEA, prompting concern about the lost EU opportunity and a selloff. Some traders view the reaction as an overreaction and point to U.S. launch demand and upcoming sales results as the key test, while others remain wary about whether U.S. growth can offset the setback.

Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

Equity

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. 


Futures Rise As Warsh Stays Mum, Tesla "Flying Car" Interrupts AI Liquidation

Futures Rise As Warsh Stays Mum, Tesla "Flying Car" Interrupts AI Liquidation

 US futures are higher, and small caps are leading, as the crowded-trade unwind that hammered chips, momentum and AI baskets all week takes a breather: Fed Chair Kevin Warsh said nothing about rates at the IMF...

Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months

European regulators rejected Omeros’ application for Narsoplimab, which is used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy.


Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros shares are trading lower Friday after the company announced that the EMA's CHMP upheld its negative opinion on narsoplimab for TA-TMA.read more...

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the companys marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell...

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.

This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded MetLife, Brinker, Plexus, West Pharma and Omeros, raising ratings and price targets.read more...

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Omeros (OMER) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Bullish Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright views the weakness following the morning’s negative Committee for Medicinal Products for Human Use opinion as overdone and sees a buying opportunity ahead of the next quarterly update.</li><li>Today’s decision, H.C. Wainwright said, does not change its forecasts, valuation, or investment thesis, while reiterating a Buy rating with a $33 price target.</li><li>The company now plans to license commercialization rights to a third party in the European Union (EU) if EU marketing authorization is granted.</li></ul><p>Shares of Omeros Corp (OMER) slumped 15% on Friday after a European Medicines Agency committee upheld a negative opinion on its drug for a serious post-transplant condition, though H.C. Wainwright dismissed the selloff as overdone.</p><p>The stock is now on track for its steepest one-day decline since late June.</p><h2 class="st-heading-2">What Did The Analyst Say?</h2><p>H.C. Wainwright views the weakness following the morning’s negative Committee for Medicinal Products for Human Use opinion as overdone and sees a buying opportunity ahead of the next quarterly update. The firm said it had already removed Europe entirely from its model when it lowered its price target to $33 in June after the committee's initial negative opinion.</p><p>Today’s decision, H.C. Wainwright said, does not change its forecasts, valuation, or investment thesis, while reiterating a Buy rating with a $33 price target. The price target still implies a potential upside of about 100% from the stock’s current trading levels around $16.</p><h2 class="st-heading-2">Second European Rejection For Yartemlea</h2><p>The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. This followed a re-examination of the committee’s original negative decision from June.</p><p>An eight-member ad hoc expert group recommended that outside experts examine individual patient data to better understand factors linked to treatment response and survival, the company said. Omeros said it had submitted substantial patient-level data in August, but the CHMP did not share those records with the expert panel.</p><h2 class="st-heading-2">US Approval Stands In Contrast</h2><p>Narsoplimab targets a rare and potentially fatal complication called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), which damages small blood vessels after stem cell transplants. The U.S. Food and Drug Administration approved it in December 2025 as the first and only treatment for the condition in patients aged two and older. No approved therapy exists for TA-TMA in Europe.</p><p>“We are deeply disappointed in the re-examination process and outcome,” said Omeros CEO Gregory A. Demopulos.</p><p>The company also said that it will terminate the compassionate use program for the drug in the EU and focus on its U.S. market. Current patients will receive enough supply to finish treatment, Omeros added.</p><p>The company now plans to license commercialization rights to a third party in the European Union (EU) if EU marketing authorization is granted.</p><h2 class="st-heading-2">How Did OMER Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$OMER" data-symbol-id="OMER" href="https://stocktwits.com/symbol/OMER" target="_blank">OMER stock</a> stayed within the bearish territory over the past 24 hours, while message volume rose from normal to high levels.</p><p>A Stocktwits user noted that the company has a partnership in place with Danish drugmaker Novo Nordisk for another drug called zaltenibart, which will eventually bring in milestone payments.</p><p><stembedurl>https://stocktwits.com/resq1/message/666714149</stembedurl></p><p>Another user said they weren't expecting “this big of a downward move.”</p><p><stembedurl>https://stocktwits.com/Chronite/message/666685540</stembedurl></p><p>OMER stock has fallen 6% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/xom-stock-climbs-on-4-5-b-refining-lift-estimate-goldman-sees-q3-eps-exceeding-wall-street-expectations/cZxKaeZRBsU">XOM Stock Climbs On $4.5B Refining Lift Estimate; Goldman Sees Q3 EPS Exceeding Wall Street Expectations</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. 

iShares Russell 2000 ETF

Omeros Corp

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$16.55
Prev Close	$16.35
Open	$16.42
Dividend Yield	0.00%
50-Day Moving Average	$18.41
Beta	1.44
Avg. Volume	1.52M
PE Ratio	11.51

52-Week High	$21.24
52-Week Low	$6.24
Market Capitalization	$1.18B
EPS (Annual)	-$0.0528
Price to Book	-23.23
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OMER Fundamentals